

1 **The prevalence of cardiovascular disease risk factors among adults living in**
2 **extreme poverty: a cross-sectional analysis of 105 nationally representative**
3 **surveys with 33 million participants**

4 **Authors:** Pascal Geldsetzer^{1,2,†*}, Rebecca L. Tisdale^{3,4,†}, Lisa Stehr⁵, Felix Michalik^{1,5}, Julia
5 Lemp⁵, Krishna K. Aryal⁶, Albertino Damasceno⁷, Corine Houehanou⁸, Jutta Mari Adelin
6 Jørgensen⁹, Nuno Lunet⁷, Mary Mayige¹⁰, Sahar Saeedi Moghaddam¹¹, Joseph Kibachio
7 Mwangi¹², Christian Bommer^{5,13}, Maja-Emilia Marcus^{13,14}, Michaela Theilmann⁵, Rifat
8 Atun^{15,16}, Justine Ina Davies^{17,18,19}, David Flood²⁰, Jennifer Manne-Goehler^{21,22}, Jacqueline
9 Seiglie^{23,24}, Till Bärnighausen^{5,25,†}, Sebastian Vollmer^{13,14,†}

10 **Affiliations:**

11 ¹Department of Medicine, Division of Primary Care and Population Health, Stanford
12 University School of Medicine; Stanford, CA, USA

13 ²Chan Zuckerberg Biohub; San Francisco, CA, USA

14 ³Veterans Affairs Palo Alto Health Care System; Palo Alto, CA, USA

15 ⁴Department of Health Policy, Stanford University School of Medicine, and Center for
16 Health Policy, Freeman Spogli Institute for International Studies, Stanford University;
17 Stanford, CA, USA

18 ⁵Heidelberg Institute of Global Health, Faculty of Medicine and University Hospital,
19 Heidelberg University, Heidelberg, Germany

20 ⁶Department for International Development/Nepal Health Sector Programme 3/Monitoring
21 Evaluation and Operational Research, Abt Associates, Kathmandu, Nepal

22 ⁷Department of Public and Forensic Health Sciences and Medical Education, Faculty of
23 Medicine, University of Porto, Porto, Portugal

24 ⁸Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health
25 Sciences, University of Abomey-Calavi, Cotonou, Benin

26 ⁹Institute of Global Health, Dept of Public Health and Epidemiology, Copenhagen
27 University, Denmark

28 ¹⁰National Institute for Medical Research, Dar es Salaam, Tanzania

29 ¹¹Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population
30 Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

31 ¹²Division of Non-Communicable Diseases, Ministry of Health, Nairobi, Kenya

32 ¹³Centre for Modern Indian Studies, University of Goettingen, Göttingen, Germany

33 ¹⁴Department of Economics, University of Goettingen, Göttingen, Germany

34 ¹⁵Department of Global Health and Population, Harvard T. H. Chan School of Public Health,
35 Boston, MA, USA

36 ¹⁶Department of Global Health and Social Medicine, Harvard Medical School, Harvard
37 University, Boston, MA, USA

1 ¹⁷Institute of Applied Health Research, University of Birmingham, Birmingham, United
2 Kingdom

3 ¹⁸MRC/Wits Rural Public Health and Health Transitions Research Unit, School of Public
4 Health, University of the Witwatersrand, Johannesburg, South Africa

5 ¹⁹Centre for Global Surgery, Department of Global Health, Stellenbosch University, Cape
6 Town, South Africa

7 ²⁰University of Michigan, Ann Arbor, MI, USA

8 ²¹Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA

9 ²²Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical
10 School, Boston, MA, USA

11 ²³Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA

12 ²⁴Department of Medicine, Harvard Medical School, Boston, MA, USA

13 ²⁵Harvard Center for Population and Development Studies, Cambridge, MA, USA

14
15 *Corresponding author. Email: pgeldsetzer @stanford.edu

16
17 †These authors contributed equally to this work and share first authorship.

18 ‡These authors contributed equally to this work and share senior authorship.

19
20

Abstract

Background: Historically, the international development community has often held the view that those living in extreme poverty (at less than \$1.90/day) are likely to have a low prevalence of cardiovascular disease (CVD) risk factors due to calorie scarcity, a largely plant-based diet, and physical labor. Evidence on CVD risk factor prevalence among adults living below the World Bank's international line for extreme poverty globally is sparse because studies have used measures of socioeconomic status that are not comparable across study populations and countries. For adults living in extreme poverty, this study aimed to determine i) the prevalence of each of five key CVD risk factors, ii) how the prevalence of these CVD risk factors varies across and within countries, and iii) the level of treatment coverage with statin, antihypertensive, and diabetes therapy.

Methods: We pooled individual-level data from 105 nationally representative household surveys with physical measurements of hypertension, diabetes, overweight, obesity, and dyslipidemia, as well as self-reported smoking status, from 78 countries that represent 85% of people living in extreme poverty globally. Those living in extreme poverty were defined by ordering participants according to a continuous household wealth index or household income value, and then applying World Bank estimates on the proportion of each country's population that is living in extreme poverty. We used modified Poisson regression models to examine how CVD risk factor prevalence among those in extreme poverty varied by age, sex, educational attainment, and rural versus urban residency. We also calculated the proportion of participants with diabetes or hypertension who self-reported the use of blood pressure- or blood glucose-lowering medication, respectively; the proportion with hypertension who achieved blood pressure control; and the proportion recommended for statin use according to WHO guidelines who reported taking a statin.

Results: Of 32,695,579 participants, 7,922,289 were living in extreme poverty (<\$1.90 per day), 15,986,099 on less than \$3.20/day, and 23,466,879 on less than \$5.50/day. Among those living in extreme poverty (<\$1.90 per day), the age-standardized prevalence was 17.5% (95% CI: 16.7% – 18.3%) for hypertension, 4.0% (95% CI: 3.6% – 4.5%) for diabetes, 10.6% (95% CI: 9.0% – 12.3%) for current smoking, 3.1% (95% CI: 2.8% – 3.3%) for obesity, and 1.4% (95% CI: 0.9% – 1.9%) for dyslipidemia. In most countries in our analysis, the prevalence of these risk factors among those living in extreme poverty was not notably lower than in the total population. Hypertension treatment and control, diabetes treatment, and statin use were low across all poverty levels in low-income countries, while in lower and upper middle-income countries individuals living at more extreme levels of poverty had a lower probability of reporting the use of these medications and achieving hypertension control.

Conclusions: We found a high prevalence of CVD risk factors among adults living below the World Bank's international line for extreme poverty, along with low statin use and low treatment rates for diabetes and hypertension. Our detailed analysis and comparison across poverty levels could inform equity discussions for resource allocation and the design of effective interventions.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

1 **Background**

2 The prevalence of cardiovascular disease (CVD) risk factors among those living in extreme
3 poverty in low- and middle-income countries (LMICs) has often been assumed to be low^{1,2}.
4 Historically, this subpopulation has been thought to take in fewer calories and have
5 correspondingly lower body mass index³⁻⁷, consume a largely plant-based diet^{3,7-11} and earn
6 income through occupations associated with higher physical activity^{3,6,12,13}. All of these lifestyle
7 patterns decrease the risk of developing CVD and its risk factors¹⁴.

8 Understanding the extent to which this assumption of a low prevalence of CVD risk factors
9 among those in extreme poverty holds true is important for setting priorities within health policy
10 and care delivery, both for equity and effectiveness. From an equity perspective, if CVD risk
11 factors mostly affect wealthier population groups in LMICs, then investing in programs aimed at
12 preventing and treating CVD instead of focusing on those conditions that disproportionately
13 affect those in extreme poverty could further worsen health inequalities by wealth. Regarding
14 effectiveness, understanding the prevalence of CVD risk factors in different population groups is
15 essential for the tailoring of appropriate interventions. For instance, if the prevalence of treatable
16 CVD risk factors, such as diabetes and hypertension, is high among those living in extreme
17 poverty but their engagement with the healthcare system for these conditions is low, then
18 programs that identify ways to engage this population in screening and long-term care for these
19 conditions will be needed.

20 Despite the importance of this information for guiding health policy and healthcare delivery, to
21 date little data from nationally representative surveys on CVD risk factor prevalence among
22 adults living in extreme poverty exist^{15,16}. The few studies that do exist employ one of two types
23 of measures of poverty. A subset of the literature relies on relative measures of poverty,
24 particularly household wealth quintiles^{15,16} or tertiles^{17,18}. These measures are specific to the
25 population in which they are calculated because they are relative categories (i.e., the absolute
26 difference in the degree of poverty between a given set of household wealth quintiles will vary
27 across populations) and based on dwelling characteristics and household ownership of durable
28 goods that are inherently context-specific¹⁹. They, thus, have limited value in informing CVD
29 risk factor prevalence among those living below an absolute threshold of poverty, such as the
30 World Bank's international poverty line for extreme poverty²⁰. A second body of literature uses
31 educational attainment as a measure of poverty^{15-17,21-23}. This approach has two critical
32 limitations. First and foremost, education is an imperfect proxy for poverty. For instance, a given
33 individual's education is unlikely to change later in life²⁴, yet that individual's economic status
34 could change significantly over the decades after leaving school. Second, quality of education
35 varies widely across and within countries in LMICs^{25,26}, such that years of schooling or a given
36 school degree hold little information outside of specific settings.

37 This study overcomes these limitations of sparse nationally representative data and poverty
38 measures that are not comparable across settings. We have brought together and harmonized 105
39 nationally representative surveys with (except for smoking) physical measurements on five
40 major CVD risk factors (diabetes, dyslipidemia, hypertension, obesity, and smoking) from 78
41 LMICs. This is by far the largest and most comprehensive analysis of the relationship between
42 poverty and CVD risk factors to date. The countries included in our dataset are estimated to be
43 home to 85% of individuals living in extreme poverty worldwide^{27,28}, and represent 53% of the
44 global population as well as 64% of the global population living in LMICs²⁸. By harnessing the
45 national representativeness of our data, we employ a consistent definition of extreme poverty
46 across countries such that we are, for the first time, able to provide estimates of CVD risk factor

1 prevalence among adults living in extreme poverty globally. Specifically, for adults living in
2 extreme poverty in our study countries, this study aimed to determine i) the prevalence of each of
3 five key CVD risk factors (and how these prevalence estimates compare to population groups
4 with higher levels of income), ii) how the prevalence of these CVD risk factors varies across and
5 within countries, and iii) the level of treatment coverage with statin, antihypertensive, and
6 diabetes therapy.

8 **Methods**

9 *Data sources*

10 To identify relevant surveys, we first searched the Stepwise Approach to Surveillance (STEPS)
11 database of the World Health Organization (WHO) and systematically searched for surveys
12 conducted by the Demographic and Health Surveys (DHS) program and the WHO Global Adult
13 Tobacco Survey (GATS) initiative (Supplementary Materials and Methods 1). STEPS, DHS, and
14 GATS surveys each utilize standardized questionnaires. Our search was limited to countries
15 designated LMICs at the time of data collection based on the World Bank income classification
16 ²⁹. For inclusion, we required that surveys: (1) be conducted during or after 2005; (2) be
17 nationally representative with a response rate >50%; (3) provide individual-level data; (4)
18 measured at least one of the following risk factors using the measure in parentheses:
19 hypertension (blood pressure), diabetes (fasting blood glucose or HbA1c), overweight/obesity
20 (height, weight), smoking (self-report via questionnaire), or dyslipidemia (total or LDL
21 cholesterol); and (5) include a measurement of household income (self-reported household
22 income or a household wealth index based on questionnaire responses to a household's
23 ownership of selected assets, materials used for housing construction, and types of water access
24 and sanitation facilities) (Supplementary Materials and Methods 1). If an eligible STEPS, DHS,
25 or GATS dataset was not available for an LMIC, or we could not gain access to the individual-
26 level data, we conducted a systematic search with Google to identify eligible surveys for the
27 given country (Supplementary Materials and Methods 1).

28 Our search returned 54 STEPS surveys, 103 DHS surveys, 30 GATS surveys, and 9 surveys via
29 the Google search that met our inclusion criteria. When more than one survey measured a CVD
30 risk factor in a given country, we used the survey that was conducted more recently for that CVD
31 risk factor. If survey collection years were identical, we used the survey that sampled a wider age
32 range of participants. Through this process (detailed in Figures S1-S4), we arrived at a total of
33 105 surveys for our analysis, of which 36 were STEPS surveys, 51 DHS surveys, 12 GATS
34 surveys and six other types of surveys.

35 The sampling strategy used by each survey included in our analysis is detailed in Supplementary
36 Materials and Methods 2.

38 *Definition of poverty*

39 The World Bank publishes annual data on the estimated proportion of the population in each
40 country that is living below each of three poverty lines, defined by an income (all in 2011
41 purchasing-power-parity [PPP] adjusted dollars) of \$1.90 per day (the “international poverty
42 line”), \$3.20 per day, and \$5.50 per day ²⁰. Our analysis focuses on those living in extreme
43 poverty, which is generally defined by the international poverty line of \$1.90 per day ²⁰.

1 However, to enable comparison with other income groups in LMICs, we also examine the
2 prevalence of CVD risk factors for the population with an income below each \$3.20 and \$5.50
3 per day, as well as those with an income greater than \$5.50 per day. For simplicity, we refer to
4 these categorizations as “poverty levels”.

5 Sixty-seven surveys included a continuous household wealth index. This index was computed
6 from a principal component analysis of participants’ answers to questions on key household
7 dwelling characteristics and household ownership of durable goods (i.e., goods that are not
8 completely consumed in one use). Most STEPS surveys instead asked participants for their
9 household’s income, allowing participants to provide the income as a yearly, monthly, or weekly
10 figure.

11 Given that the surveys included in our analysis were all nationally representative, we used the
12 distribution of household wealth or income in each survey dataset to define which participants
13 fell below each poverty level. Specifically, we first ordered participants in each dataset from
14 “poorest” to “richest” by their value of the (continuous) household wealth index or income. We
15 then used the World Bank’s estimate for the proportion of the population in the given country
16 (for the year of the survey’s data collection) that fell below each poverty level (the “poverty
17 headcount ratio”) to select a given proportion (after applying sampling weights) of the
18 participants with the lowest household wealth or income values. For example, in a dataset with
19 5,000 participants for a country with a poverty headcount ratio of 10% for extreme poverty
20 (\$1.90 per day) in the year of the survey’s data collection, we determined that the 500
21 participants with the lowest household wealth or income value were living in extreme poverty.
22 Details on the household wealth and income measures available in each survey, and our
23 calculation to assign a poverty level to each participant, are provided in Table S13 and
24 Supplementary Materials and Methods 5.4.

25 26 *Definition of CVD risk factors and statin use*

27 *Hypertension*

28 Of the 50 surveys that we used to estimate hypertension prevalence, 37 surveys used a digital
29 upper arm meter for blood pressure (BP) measurements, one survey a digital wrist meter, and
30 one a manual mercury sphygmomanometer (Supplementary Materials and Methods 3.1, Table
31 S2). For 11 countries, the BP measurement device was not stated in the survey documentation.
32 BP was measured three times in 46 countries, three countries undertook two measurements, and
33 one country measured twice inducing a third measurement if the first two differed by more than
34 10 mmHg. Based on established usage in LMICs and following the recommendations of the
35 International Society of Hypertension, we defined hypertension as systolic BP ≥ 140 mmHg,
36 diastolic BP ≥ 90 mmHg, or reporting to be taking medication to lower BP³⁰. If three BP
37 measurements were available, the mean of the last two was employed, and averages were used
38 for surveys with two measurements.

39 40 *Diabetes*

41 Of the 42 surveys that we used to estimate diabetes prevalence, 30 surveys used a point-of-care
42 fasting capillary glucose measurement, three surveys used a laboratory-based assessment of
43 fasting plasma glucose, and nine surveys measured HbA1c (Supplementary Materials and
44 Methods 3.2, Table S3). Following clinical lab standards and published guidelines³¹, we used

1 plasma equivalents for our analysis by multiplying capillary glucose values by 1.11 in those
2 eight surveys that did not provide plasma equivalents. Based on the WHO diagnostic criteria,
3 respondents were diagnosed with diabetes if they had either (1) a fasting plasma glucose of 7.0
4 mmol/l (126 mg/dl) or higher, (2) a plasma glucose of 11.1 mmol/l (200 mg/dl) or higher with no
5 fasting, (3) HbA1c records of 6.5% or higher, or (4) reported to take medication for diabetes³².
6 In the 17 surveys for which information on fasting status was missing, we assumed participants
7 to be fasting, thereby complying with the fasting instructions that were given in all surveys.

8 9 *Overweight and obesity*

10 Height and weight were measured by trained personnel in all 72 surveys that we used to estimate
11 overweight and obesity prevalence. Details on height and weight measurements for each survey
12 are given in Supplementary Materials and Methods 3.3, and Table S4. Following WHO
13 classifications, we defined overweight as a body mass index (BMI) of 25.0 to <30.0 kg/m² and
14 obesity as a BMI ≥30.0 kg/m²³³.

15 16 *Smoking*

17 In the 73 surveys that we used to estimate smoking prevalence, we defined current smoking as
18 stating to be a current smoker of cigarettes or other smoked tobacco products. The specific
19 questions used to define smoking in each survey are detailed in Supplementary Materials and
20 Methods 3.4. and Table S5.

21 22 *Dyslipidemia*

23 Cholesterol measurements were taken using point-of-care devices (see Supplementary Materials
24 and Methods 3.5 and Table S6 for details). We used total cholesterol and low-density lipoprotein
25 (LDL) to determine dyslipidemia. Of the 32 surveys that we used to estimate dyslipidemia
26 prevalence, five had measured both total and LDL cholesterol while the remaining 27 surveys
27 only measured total cholesterol. In the 27 surveys that did not measure LDL but did measure
28 total cholesterol, triglycerides, and high-density lipoprotein (HDL), we used the Friedewald
29 equation to estimate LDL for each participant³⁴. Following the National Cholesterol Education
30 Program's Adult Treatment Panel III (ATP III) guidelines³⁵, we defined dyslipidemia as (1)
31 having a total cholesterol above 240 mg/dL, (2) self-reporting the use of lipid-lowering
32 medication, or (3) having an LDL higher than 160 mg/dL. More details on the measurement of
33 blood lipids and definition of dyslipidemia in each survey are provided in Supplementary
34 Materials and Methods 3.5. and 5.1.

35 36 *Statin use*

37 Nineteen surveys collected data on statin use. The questions used to determine statin use and
38 CVD history in each survey are detailed in Supplementary Materials and Methods 3.8.

39 40 *Statistical analysis*

1 We used age-standardized sampling weights for all prevalence estimates, weighting to the age
2 structure of the WHO standard reference population³⁶. When providing estimates across all
3 included countries, by World Bank country income group, or by world region, we additionally
4 weighted countries according to the proportion of all individuals globally living below the given
5 poverty level who reside in the given country (as estimated using the World Bank's poverty
6 headcount ratio and the United Nation's population size estimates^{27,37}). All analyses were
7 restricted to non-pregnant participants aged 15 years or older.

8 Our analysis had four steps. First, we estimated the prevalence of each CVD risk factor by
9 poverty level (income <\$1.90/day, <\$3.20/day, <\$5.50/day, >\$5.50/day, or total population) and
10 World Bank country income group in the year of the survey's data collection (low-income, lower
11 middle-income, or upper middle-income)²⁹.

12 Second, to determine how the prevalence of each CVD risk factor varied by individual-level
13 characteristics among those living in extreme poverty, we regressed each CVD risk factor onto
14 age, sex, educational attainment, and rural versus urban residency (both jointly in covariate-
15 adjusted regression and separately in covariate-unadjusted regressions). We used Poisson
16 regression models with a robust error structure, country-level fixed effects, and restricted cubic
17 splines with five knots for age (placed at the 5th, 27.5th, 50th, 72.5th, and 95th percentile).

18 Education was categorized as "no formal schooling", "primary education" (\leq grade 6), and
19 "secondary education (grade 7 to 12) or further", using local education classifications whenever
20 available, and years of education in cases where categorical variables were unavailable. More
21 detail on the creation of the education variable is provided in Supplementary Materials and
22 Methods 4 and Tables S10-S11. Standard errors were adjusted for clustering at the level of the
23 primary sampling unit (usually a village or neighborhood) and household.

24 Third, we examined how the prevalence of each CVD risk factor among those living in extreme
25 poverty varied by a country's level of economic development (as estimated using GDP per capita
26 in the year of the survey's data collection³⁸) and a country's "poverty intensity". We use the
27 term "poverty intensity" in this manuscript to refer to the mean daily income (in 2011 PPP-
28 adjusted dollars) among those living in extreme poverty, as estimated by the World Bank for the
29 year of the survey's data collection³⁹. It is, thus, a measure of the depth of poverty among those
30 below the poverty line of \$1.90 per day. To do so, we plotted the prevalence of each CVD risk
31 factor in a country against the country's GDP per capita and the country's poverty intensity
32 among those living in extreme poverty.

33 Fourth, to ascertain the level of treatment coverage for CVD risk reduction among those living in
34 extreme poverty, we calculated the proportion of participants that self-reported the use of
35 medication to lower BP or blood glucose levels among those with hypertension and diabetes,
36 respectively. In addition, among those with hypertension who reported to be taking BP-lowering
37 medication, we computed the proportion that had a systolic BP <140 mmHg and a diastolic BP
38 <90 mmHg (henceforth referred to as "controlled hypertension"). Lastly, we calculated treatment
39 coverage with statin medication following the WHO guidelines for recommended statin use⁴⁰.

40 To do so, we computed the proportion of participants: i) with a history of CVD (see
41 Supplementary Materials and Methods 3.8 for the questions used in each survey to ascertain
42 CVD history) who reported to be taking a statin medication (statin use for secondary prevention),
43 and ii) who were 40 years or older with either a diagnosis of diabetes or a ten-year CVD risk
44 greater than 20% (as per the 2019 WHO laboratory-based risk equations⁴¹; statin use for primary
45 prevention). More detail on the analyses for this fourth step is provided in Supplementary
46 Materials and Methods 5.3.

1 This analysis was considered exempt for not-human-subjects research by the institutional review
2 boards at the Stanford University School of Medicine and the Heidelberg University Medical
3 Faculty.

4 5 *Data availability*

6 This study includes individual-level data from 105 surveys. Data are publicly available for 102
7 of these surveys. For data that are not publicly accessible and for which we have arranged
8 specific data-use agreements, we are unable to share these data given the terms of our
9 agreements. All data management and analysis code will be posted in a public repository upon
10 acceptance of the manuscript.

11 12 **Results**

13 *Sample characteristics*

14 Our analysis included 105 surveys with a total sample size of 32,695,579 participants (**Table 1**).
15 The survey-level median age of participants was 35.0 years with a survey-level interquartile
16 range of 32.0 to 39.0 years. Of these 32,695,579 participants, 7,922,289 were living in extreme
17 poverty (<\$1.90 per day), 15,986,099 on less than \$3.20/day, and 23,466,879 on less than
18 \$5.50/day. The median survey response rate was 96.3%, ranging from 91.0% to 98.8%.

19 20 *Prevalence of CVD risk factors among adults living in extreme poverty*

21 Across all our study countries, the age-standardized prevalence of each CVD risk factor among
22 those living in extreme poverty (<\$1.90 per day) was 17.5% (95% CI: 16.7% – 18.3%) for
23 hypertension, 4.0% (95% CI: 3.6% – 4.5%) for diabetes, 10.6% (95% CI: 9.0% – 12.3%) for
24 current smoking, 3.1% (95% CI: 2.8% – 3.3%) for obesity, and 1.4% (95% CI: 0.9% – 1.9%) for
25 dyslipidemia (Table S14).

26 Stratified by World Bank country income category, **Figure 1** compares the prevalence of each
27 CVD risk factor among those living in extreme poverty (<\$1.90 per day) to the prevalence
28 among the entire population, as well as those living below \$3.20 per day, below \$5.50 per day,
29 and above \$5.50 per day. With the exception of current smoking, obesity, and dyslipidemia in
30 lower middle-income countries, the prevalence of each CVD risk factor among those living in
31 extreme poverty (<\$1.90 per day) was not notably lower than in the total population, and
32 frequently even exceeded the prevalence in the total population. The prevalence of *hypertension*
33 was above ten percent among each population income group in Figure 1 in low-income, lower
34 middle-income, and upper middle-income countries, with relative differences between these
35 population groups being comparatively small. Similarly, differences in the prevalence of
36 *diabetes* across population income groups did not exceed six percentage points. A clear gradient
37 wherein those with higher incomes had a higher prevalence of diabetes was only apparent in
38 lower middle-income countries. The prevalence of *current smoking* was low across population
39 income groups in low-income countries, and high across population income groups in upper
40 middle-income countries. As for diabetes, we observed an income gradient in the prevalence of
41 current smoking in lower middle-income countries wherein individuals with higher incomes
42 were more likely to smoke. The prevalence of *obesity* displayed a similarly positive income
43 gradient across all World Bank country categories. The prevalence of *dyslipidemia* was below

1 three percent among each population income group in low-income countries and above ten
2 percent among each population income group in upper middle-income countries. In lower
3 middle-income countries, the prevalence of dyslipidemia had a strong positive income gradient.

4
5 ***Variation in CVD risk factor prevalence among those living in extreme poverty by sex,***
6 ***education, and rural-urban residency***

7 Among participants living in extreme poverty, only diabetes was associated with differential
8 prevalence by rurality, with urban dwellers at higher risk (RR: 1.47 [95% CI: 1.08 – 2.00])
9 (**Figure 2**). When stratifying those living in extreme poverty by sex, men had a slightly higher
10 prevalence of hypertension (RR: 1.09 [95% CI: 1.01 – 1.17]), a substantially lower prevalence of
11 obesity (RR: 0.36 [95% CI: 0.24 – 0.54]), and a far higher prevalence of smoking (RR: 13.16
12 [95% CI: 10.37 – 16.70]) than women. No significant differences in CVD risk factor prevalence
13 were seen by education level except for smoking, which was more common among those in
14 extreme poverty with a high school education or above compared to those with no schooling
15 (RR: 1.45 [95% CI: 1.22 – 1.74]).

16
17 ***Association of CVD risk factor prevalence among those living in extreme poverty with a***
18 ***country's economic development and intensity of poverty***

19 The prevalence of overweight and obesity among those living in extreme poverty (<\$1.90 per
20 day) was positively associated with a country's level of economic development (GDP per capita)
21 as well as the mean daily income of those living in extreme poverty in a country (i.e., the less
22 "intense" the mean level of poverty among those living in extreme poverty in a country, the
23 higher was the prevalence of overweight and obesity among those living in extreme poverty)
24 (**Figure 3**). A country's economic development and poverty intensity was not significantly
25 correlated with the prevalence of hypertension and diabetes among those living in extreme
26 poverty. Current smoking was positively associated with a country's mean daily income among
27 those living in extreme poverty. Analogous analyses as in Figure 3, but for those living below
28 \$3.20 per day and \$5.50 per day, are shown in Figures S11-S13, and demonstrated similar
29 patterns.

30
31 ***Treatment of CVD risk among those living in extreme poverty***

32 Among those living in extreme poverty (<\$1.90/day) who had hypertension, 15.2% (95% CI:
33 13.3% – 17.1%) reported taking BP-lowering medication and 5.7% (95% CI: 4.7% – 6.7%) had
34 achieved hypertension control (i.e., systolic BP <140 mmHg and diastolic BP <90 mmHg).
35 19.7% (95% CI: 15.3% – 24.1%) of those living in extreme poverty (<\$1.90/day) with diabetes
36 reported taking blood glucose-lowering medication. Among those living in extreme poverty
37 (<\$1.90/day) who should be taking a statin for secondary prevention of CVD according to WHO
38 guidelines, only 1.1% (95% CI: 0.4% – 1.9%) were doing so. In low-income countries,
39 hypertension treatment and control, diabetes treatment, and statin use were low among each
40 poverty level (**Figure 4**). In lower middle-income countries, individuals living at more extreme
41 levels of poverty had a consistently lower probability of being on treatment for their
42 hypertension and diabetes, achieving hypertension control, and using statins for primary or
43 secondary prevention of CVD. These gradients by poverty level were less pronounced in upper

1 middle-income countries, where instead the difference between those at any poverty level of less
2 than <\$5.50/day versus living on >\$5.50/day tended to be the largest.

3 4 **Discussion**

5 Our analysis of nationally representative survey data on CVD risk factors from 78 LMICs that
6 are home to the vast majority (an estimated 85%^{27,28}) of individuals living in extreme poverty
7 globally generally found a high prevalence of CVD risk factors among this population group. In
8 fact, in most countries included in our analysis, the prevalence of these risk factors among those
9 living in extreme poverty was not notably lower than in the total population. Our findings thus
10 contradict the common assumption that the environment (e.g., food scarcity³⁻⁷) and lifestyles
11 (e.g., more physical labor^{3,6,12,13}) of those living in extreme poverty in LMICs results in a
12 minimal prevalence of CVD risk factors among this group. At the same time, we find marked
13 positive income gradients in rates of evidence-based treatment for these conditions, which
14 further increases the risk of CVD events, such as myocardial infarctions and strokes, among
15 those in extreme poverty relative to wealthier individuals in LMICs.

16 In 2015, The Lancet NCDI Poverty Commission was founded in the conviction that “non-
17 communicable diseases and injuries (NCDIs) are an important, yet an under-recognized and
18 poorly-understood contributor to the death and suffering” of the poorest billion in the world⁴².
19 Focusing largely on the political, economic, and financing aspects of addressing NCDIs in
20 LMICs⁴², the commission restricted its quantitative analyses on the prevalence of NCDIs and its
21 risk factors among the poorest billion merely to data from seven Health and Demographic
22 Surveillance Sites (each representative for populations ranging in size from 31,000 to 129,000⁴³)
23 in five countries in sub-Saharan Africa. In what is, to our knowledge, the first study to estimate
24 CVD risk factor prevalence among adults living in extreme poverty using multi-country
25 nationally representative data, this research thus provides a crucial empirical foundation for the
26 future work of this commission. At its inception, the commission hypothesized that NCDIs
27 among those in extreme poverty are more likely to be the result of infections and harmful
28 environments (e.g., exposure to environmental toxins) than behavioral risk factors⁴⁴. Although
29 we did not examine infectious and environmental risk factors, we found a comparatively high
30 prevalence of five major CVD risk factors, for which behavioral choices are thought to play an
31 important causal role^{14,45,46}, among adults in extreme poverty.

32 In addition to our findings on the overall prevalence of CVD risk factors among those living in
33 extreme poverty, our detailed analyses of how CVD risk factor prevalence and treatment
34 coverage vary by individual-level characteristics among this population group could inform the
35 effective targeting and tailoring of appropriate interventions and policies to reduce CVD risk in
36 this vulnerable group. However, because risk factors may not map perfectly or predictably onto
37 resultant CVD outcomes, such as because of competing risk from infectious causes of death, our
38 data are only suggestive of the CVD burden of those living in extreme poverty as compared to
39 that of wealthier population groups. They cannot on their own establish whether investments in
40 treating CVD risk factors in LMICs would be equitable. Nevertheless, we would like to highlight
41 five points that we believe are important when considering the equity implications of investing in
42 reducing CVD risk in LMICs. First, we found that those living in extreme poverty in LMICs not
43 only have a high prevalence of CVD risk factors but are generally also least likely to be taking
44 CVD risk-reducing medications. Second, it is likely that this vulnerable segment of society has
45 the least access to high-quality care for CVD events in most settings^{47,48}. Third, those living in

1 extreme poverty experience far greater wage losses relative to their household spending from an
2 illness episode (including for CVD) than do wealthier population groups⁴⁹. Fourth, we found
3 that the prevalence of overweight and obesity among those living in extreme poverty are
4 positively associated with a country's GDP per capita and the mean daily income among those
5 living in extreme poverty. It is, therefore, likely that as LMICs develop economically,
6 overweight and obesity prevalence among the poorest segments of their societies will increase
7 and, at least partially as a result of this rise in unhealthy weight, the prevalence of diabetes,
8 dyslipidemia, and hypertension will also grow. Lastly, relative to its disease burden, care and
9 prevention for CVD, and NCDs more broadly, are currently vastly underfunded compared to
10 infectious diseases and maternal and child health^{50,51}.

11 Our study has several additional limitations. First, while the countries included in our sample
12 comprised 86% of the current global population of LMICs (as well as 85% of the global
13 population) estimated to be living in extreme poverty^{27,37}, they are not a probabilistic subset of
14 countries but were instead selected due to their data availability. They may, thus, not fully
15 represent all LMICs or adults living in extreme poverty globally. Second, the surveys were
16 conducted in different years, limiting comparability among them (although a comparison of
17 countries was not the primary objective of our study) and generalizability to the present. They
18 do, however, constitute the most recent nationally representative data available. Third, we did
19 not have detailed consumption data for our surveys, but had to rely instead on household wealth
20 indices or data on household income to define extreme poverty. In a subset of 38 surveys in
21 which we did not have a household wealth index, we used self-reported household income to
22 define poverty. This is a limitation in so far as households in LMICs commonly have multiple
23 income sources (complicating calculations for participants) and varying income between
24 different years⁵². In addition, we were unable to adjust household income based on household
25 size in this subset of 38 surveys due to a lack of consistent information on the number of
26 household members and their age across surveys. In 19 of these 38 surveys, the survey for which
27 we had to use total household income was only used for a subset of the five CVD risk factors
28 examined in this analysis. Fourth, we did not have sufficiently detailed and homogeneous data to
29 be able to use multi-dimensional measures of poverty, such as the multi-dimensional poverty
30 index⁵³. Fifth, hypertension and diabetes were assessed in one-off measurements rather than the
31 multiple measurements that are generally recommended for a clinical diagnosis of these
32 conditions^{54,55}. Lastly, although the primary objective of our analysis was not to compare
33 countries (or surveys) with each other, it is possible that the variation in the questionnaires and
34 methodology for measuring hypertension, diabetes, and dyslipidemia across our surveys
35 introduced some level of bias in our analyses of how CVD risk factor prevalence among those
36 living in extreme poverty is associated with countries' GDP per capita and poverty intensity.
37 However, the three main sources of data used in this analysis (the DHS, STEPS, and GATS)
38 each used a standardized questionnaire and approach to measuring CVD risk factors.

39 In sum, this study demonstrates that CVD risk factors affect individuals across the full
40 socioeconomic spectrum, including those living in extreme poverty, within countries at all levels
41 of economic development. Although we did not directly assess CVD morbidity and mortality nor
42 the disease burden from non-CVD causes, our findings of a high CVD risk factor prevalence
43 along with a low coverage with CVD risk-reducing medications among those living in extreme
44 poverty suggest that equity concerns are likely misplaced in justifying the current vast
45 underfunding of CVD prevention and care compared to other health areas in LMICs^{50,51}. Our
46 unique effort of collating nationally representative data on CVD risk factors from 78 LMICs and

1 applying a consistent definition of poverty across surveys can inform not only resource
2 allocation decisions but also the design of appropriate preventive or care interventions.

References

1. Zuccala, E. & Horton, R. Reframing the NCD agenda: a matter of justice and equity. *The Lancet* **396**, 939–940 (2020).
2. Yach, D., Hawkes, C., Gould, C. L. & Hofman, K. J. The global burden of chronic diseases: overcoming impediments to prevention and control. *JAMA* **291**, 2616–2622 (2004).
3. Banerjee, A. V. & Duflo, E. The economic lives of the poor. *Journal of Economic Perspectives* **21**, 141–68 (2007).
4. Subramanian, S. & Deaton, A. The Demand for Food and Calories. *Journal of Political Economy* **104**, 133–162 (1996).
5. U, A., Akhter *et al.* *The world's most deprived: Characteristics and causes of extreme poverty and hunger*. (Intl Food Policy Res Inst, 2007).
6. Hickel, J. The true extent of global poverty and hunger: questioning the good news narrative of the Millennium Development Goals. *Third World Quarterly* **37**, 749–767 (2016).
7. Svedberg, P. *Poverty and Undernutrition: Theory, Measurement, and Policy*. (Oxford University Press, 2000).
8. Wanyama, R. N. Food Security and Dietary Patterns among the Urban Poor in Africa. (2019) doi:10.53846/goediss-7447.
9. Hassen, I. W., Dereje, M., Minten, B. & Hirvonen, K. Diet transformation in Africa: The case of Ethiopia. *International Food Policy Research Institute* (2016).
10. Our World in Data. Daily meat consumption per person. *Our World in Data* <https://ourworldindata.org/grapher/daily-meat-consumption-per-person>.
11. Our World in Data. Share of energy from cereals, roots, and tubers vs. GDP per capita. *Our World in Data* <https://ourworldindata.org/grapher/share-of-energy-from-cereals-roots-and-tubers-vs-gdp-per-capita>.
12. Gindling, T. H. & Newhouse, D. Self-Employment in the Developing World. *World Development* **56**, 313–331 (2014).
13. Collins, D., Morduch, J., Rutherford, S. & Ruthven, O. *Portfolios of the Poor: How the World's Poor Live on \$2 a Day*. *Portfolios of the Poor* (Princeton University Press, 2009). doi:10.1515/9781400829965.
14. Roth, G. A. *et al.* Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. *Journal of the American College of Cardiology* **76**, 2982–3021 (2020).
15. Allen, L. *et al.* Socioeconomic status and non-communicable disease behavioural risk factors in low-income and lower-middle-income countries: a systematic review. *The Lancet Global Health* **5**, e277–e289 (2017).
16. Williams, J. *et al.* A systematic review of associations between non-communicable diseases and socioeconomic status within low- and lower-middle-income countries. *J Glob Health* **8**,
17. Rosengren, A. *et al.* Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study. *The Lancet Global Health* **7**, e748–e760 (2019).
18. Gupta, R. *et al.* Socioeconomic factors and use of secondary preventive therapies for cardiovascular diseases in South Asia: The PURE study. *Eur J Prev Cardiol* **22**, 1261–1271 (2015).
19. Steinert, J. I., Cluver, L. D., Melendez-Torres, G. J. & Vollmer, S. One Size Fits All? The Validity of a Composite Poverty Index Across Urban and Rural Households in South Africa. *Soc Indic Res* **136**, 51–72 (2018).
20. The World Bank. *Poverty and Shared Prosperity 2018: Piecing Together the Poverty Puzzle*. <http://elibrary.worldbank.org/doi/epdf/10.1596/978-1-4648-1330-6>.

- 1 21. Goyal, A. *et al.* Attained Educational Level and Incident Atherothrombotic Events in Low-
2 and Middle-Income Compared With High-Income Countries. *Circulation* **122**, 1167–1175
3 (2010).
- 4 22. Yu, Z. Changes in cardiovascular risk factors in different socioeconomic groups: seven year
5 trends in a Chinese urban population. *Journal of Epidemiology & Community Health* **54**,
6 692–696 (2000).
- 7 23. Reddy, K. S. *et al.* Educational status and cardiovascular risk profile in Indians. *Proceedings*
8 *of the National Academy of Sciences* **104**, 16263–16268 (2007).
- 9 24. Shavers, V. L. Measurement of socioeconomic status in health disparities research. *J Natl*
10 *Med Assoc* **99**, 1013–1023 (2007).
- 11 25. Fomba, B. K., Talla, D. N. D. F. & Ningaye, P. Institutional Quality and Education Quality
12 in Developing Countries: Effects and Transmission Channels. *J Knowl Econ* (2022)
13 doi:10.1007/s13132-021-00869-9.
- 14 26. Altinok, N., Angrist, N. & Patrinos, H. A. *Global Data Set on Education Quality (1965–*
15 *2015)*. (World Bank, Washington, DC, 2018). doi:10.1596/1813-9450-8314.
- 16 27. The World Bank. Poverty headcount ratio at \$1.90 a day (2011 PPP) (% of population) |
17 Data. *The World Bank: Data* <https://data.worldbank.org/indicator/SI.POV.DDAY>.
- 18 28. The World Bank. Population, total | Data.
19 <https://data.worldbank.org/indicator/SP.POP.TOTL>.
- 20 29. The World Bank. World Bank Country and Lending Groups – World Bank Data Help Desk.
21 [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
22 [and-lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups).
- 23 30. Unger, T. *et al.* 2020 International Society of Hypertension Global Hypertension Practice
24 Guidelines. 24.
- 25 31. Sacks, D. B. *et al.* Guidelines and Recommendations for Laboratory Analysis in the
26 Diagnosis and Management of Diabetes Mellitus. *Clinical Chemistry* **57**, e1–e47 (2011).
- 27 32. World Health Organization & International Diabetes Federation. *Definition and diagnosis of*
28 *diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation*.
29 (2006).
- 30 33. World Health Organization. WHO | Obesity: preventing and managing the global epidemic.
31 *WHO*
32 http://www.who.int/entity/nutrition/publications/obesity/WHO_TRS_894/en/index.html.
- 33 34. Friedewald, W. T., Levy, R. I. & Fredrickson, D. S. Estimation of the Concentration of Low-
34 Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge.
35 *Clinical Chemistry* **18**, 499–502 (1972).
- 36 35. National Institutes of Health. *National Cholesterol Education Program E. Detection,*
37 *Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) -*
38 *Final Report*. [https://www.nhlbi.nih.gov/files/docs/resources/heart/atp-3-cholesterol-full-](https://www.nhlbi.nih.gov/files/docs/resources/heart/atp-3-cholesterol-full-report.pdf)
39 [report.pdf](https://www.nhlbi.nih.gov/files/docs/resources/heart/atp-3-cholesterol-full-report.pdf) (2001).
- 40 36. Ahmad, O. B., Boschi-pinto, C., Lopez, A. D., Lozano, R. & Inoue, M. Age standardization
41 of rates: a new WHO standard. in *Geneva: World Health Organization; 2000 (GPE*
42 *Discussion Paper No* (2009).
- 43 37. United Nations Department of Economic and Social Affairs. World Population Prospects
44 2022. <https://population.un.org/wpp/Download/Standard/Population/> (2022).
- 45 38. The World Bank. World Development Indicators. GDP per capita, PPP (constant 2011
46 international \$) [Data file]. (2020).
- 47 39. The World Bank. Poverty gap at \$1.90 a day (2011 PPP) (%) | Data.
48 <https://data.worldbank.org/indicator/SI.POV.GAPS>.

- 1 40. World Health Organization. WHO package of essential noncommunicable (PEN) disease
2 interventions for primary health care. [https://www.who.int/publications-detail-redirect/who-](https://www.who.int/publications-detail-redirect/who-package-of-essential-noncommunicable-(pen)-disease-interventions-for-primary-health-care)
3 [package-of-essential-noncommunicable-\(pen\)-disease-interventions-for-primary-health-care.](https://www.who.int/publications-detail-redirect/who-package-of-essential-noncommunicable-(pen)-disease-interventions-for-primary-health-care)
- 4 41. The WHO CVD Risk Chart Working Group. World Health Organization cardiovascular
5 disease risk charts: revised models to estimate risk in 21 global regions. *Lancet Glob Health*
6 **7**, e1332–e1345 (2019).
- 7 42. Bukhman, G. *et al.* The Lancet NCDI Poverty Commission: bridging a gap in universal
8 health coverage for the poorest billion. *The Lancet* **396**, 991–1044 (2020).
- 9 43. MEMBER HDSSs | INDEPTH Network. [http://www.indepth-network.org/member-centres.](http://www.indepth-network.org/member-centres)
- 10 44. Bukhman, G., Mocumbi, A. O. & Horton, R. Reframing NCDs and injuries for the poorest
11 billion: a Lancet Commission. *The Lancet* **386**, 1221–1222 (2015).
- 12 45. Chomistek, A. K. *et al.* Healthy lifestyle in the primordial prevention of
13 cardiovascular disease among young women. *J Am Coll Cardiol* **65**, 43–51 (2015).
- 14 46. Heath, L., Jebb, S. A., Aveyard, P. & Piernas, C. Obesity, metabolic risk and adherence to
15 healthy lifestyle behaviours: prospective cohort study in the UK Biobank. *BMC Medicine* **20**,
16 65 (2022).
- 17 47. Di Cesare, M. *et al.* Inequalities in non-communicable diseases and effective responses. *The*
18 *Lancet* **381**, 585–597 (2013).
- 19 48. Kruk, M. E. *et al.* High-quality health systems in the Sustainable Development Goals era:
20 time for a revolution. *The Lancet Global Health* **6**, e1196–e1252 (2018).
- 21 49. Srinivas, A., Jalota, S., Mahajan, A. & Miller, G. Illness and Wage Loss: Longitudinal
22 evidence from India (and Implications for the Universal Health Coverage Agenda).
23 2021.11.04.21265892 Preprint at <https://doi.org/10.1101/2021.11.04.21265892> (2021).
- 24 50. Dieleman, J. L. *et al.* Sources and Focus of Health Development Assistance, 1990–2014.
25 *JAMA* **313**, 2359–2368 (2015).
- 26 51. Chang, A. Y. *et al.* Past, present, and future of global health financing: a review of
27 development assistance, government, out-of-pocket, and other private spending on health for
28 195 countries, 1995–2050. *The Lancet* **393**, 2233–2260 (2019).
- 29 52. Howe, L. D. *et al.* Measuring socio-economic position for epidemiological studies in low-
30 and middle-income countries: a methods of measurement in epidemiology paper.
31 *International Journal of Epidemiology* **41**, 871–886 (2012).
- 32 53. Oxford Poverty & Human Development Initiative & United Nations Development
33 Programme. *Global Multidimensional Poverty Index 2021: Unmasking disparities by*
34 *ethnicity, caste and gender*. https://hdr.undp.org/sites/default/files/2021_mpi_report_en.pdf
35 (2021).
- 36 54. Whelton, P. K. *et al.* 2017
37 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the
38 Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A
39 Report of the American College of Cardiology/American Heart Association Task Force on
40 Clinical Practice Guidelines. *Hypertension* **71**, (2018).
- 41 55. American Diabetes Association Professional Practice Committee. 2. Classification and
42 Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022. *Diabetes Care* **45**,
43 S17–S38 (2021).
- 44 56. The World Bank. Poverty headcount ratio at \$3.20 a day (2011 PPP) (% of population) |
45 Data. <https://data.worldbank.org/indicator/SI.POV.LMIC>.
- 46 57. The World Bank. Poverty headcount ratio at \$5.50 a day (2011 PPP) (% of population) |
47 Data. <https://data.worldbank.org/indicator/SI.POV.UMIC>.

1 **Acknowledgements:**

2 We would like to thank all participants in the household surveys that have been harmonized and
3 analyzed in this study.

4
5 **Funding:**

6 Chan Zuckerberg Biohub (PG)

7 Veterans Affairs Office of Academic Affairs Advanced Fellowship in Health Services Research
8 (RLT)

9 Alexander-von-Humboldt university professorship through the Alexander von Humboldt
10 Foundation (TB)

11
12 **Author contributions:**

13 Conceptualization: PG, TB, SV

14 Methodology: PG, LS, FM, MM, MT, TB, SV

15 Visualization: PG, RLT, LS, FM

16 Funding acquisition: PG, TB

17 Project administration: PG, RLT, LS

18 Supervision: PG

19 Writing – original draft: PG, RLT, LS

20 Writing – review & editing: PG, RLT, LS, FM, JL, KKA, AD, CH, JMAJ, NL, MM, SSM, KJM,
21 MM, MT, JID, DF, JMG, JS, TB, SV

22
23 **Competing interests:**

24 The authors declare that they have no competing interests.

25
26 **Materials and correspondence**

27 Correspondence and materials requests should be addressed to the corresponding author (PG).

28
29 **Supplementary materials**

30 Materials and Methods

31 Supplementary Text

32 Figs. S1 to S26

33 Tables S1 to S51


34 References

35

1
2
3
4

Figures


Fig. 1. Age-standardized prevalence (in percent) of CVD risk factors by poverty level in low-income, lower middle-income, and upper middle-income countries



5
6


7 Figure 1 depicts age-standardized prevalence of CVD risk factors for those with income <\$1.90/day,
8 <\$3.20/day, <\$5.50/day, and ≥\$5.50/day for diabetes, hypertension, obesity, smoking, and dyslipidemia.
9 For dyslipidemia, the upper bound of the 95% CI for those with income ≥\$5.50/day in lower middle-
10 income countries is 37.4%. Abbreviations: inc.=income

Fig. 2. Variation in CVD risk factor prevalence among those living in extreme poverty (<\$1.90/day) by rural-urban residency, sex, and education



5 Figure 2 depicts variation in CVD risk factors among those living in extreme poverty with stratification by rurality, sex, and level of education. The risk ratio is plotted on a logarithmic scale.

Fig. 3. Associations of CVD risk factor prevalence among those living in extreme poverty (<\$1.90/day) with countries' GDP per capita and poverty intensity^{1,2,3,4}



¹Regression lines in red and confidence intervals in green indicate trends that are statistically significant ($p < 0.05$).

²The diagonal lines (in black or red) depict ordinary least-squares regressions (with each country having the same weight) of the CVD risk factor prevalence among those living in extreme poverty (<\$1.90/day) in a country onto countries' GDP per capita or mean daily income among those living on <\$1.90/day. The R^2 and p-values shown in the grey boxes refer to these ordinary least-squares regressions.

³The grey or green boundary depict the point-wise 95% prediction interval and the vertical bars are 95% confidence intervals around point estimates.


⁴GDP per capita and the mean daily income among those living on <\$1.90/day in a country was taken from the World Bank for the year of the survey's data collection^{38,39}.

Abbreviations: GDP=Gross Domestic Product; int.=international. Country abbreviations: AGO=Angola; ALB=Albania; BDI=Burundi; BEN=Benin; BOL=Bolivia; BRA=Brazil; BWA=Botswana; CHN=China; COD=Congo Democratic Republic; ECU=Ecuador; EGY=Egypt; ETH=Ethiopia; GEO=Georgia;

5 GTM=Guatemala; HND=Honduras; IND=India; IDN=Indonesia; KEN=Kenya; KGZ=Kyrgyz Republic;
KIR=Kiribati; LAO=Laos; LBR=Liberia; LSO=Lesotho; MDG=Madagascar; MEX=Mexico;
MOZ=Mozambique; MWI=Malawi; NAM=Namibia; NER=Niger; PAN=Panama; PER=Peru;
PHL=Philippines; RWA=Rwanda; STP=São Tomé and Príncipe; SLB=Solomon Islands; SWZ=Eswatini;
TCD=Chad; TGO=Togo; TJK=Tajikistan; TLS=Timor-Leste; TZA=Tanzania; VNM=Vietnam;
VUT=Vanuatu; ZAF=South Africa; ZMB=Zimbabwe

10 Figure 3 depicts associations of CVD risk factor prevalence among those living in extreme poverty (<\$1.90/day) with countries' GDP per capita and poverty intensity.

Fig. 4. Hypertension treatment and control, diabetes treatment, and statin use, by individuals' poverty level and World Bank country income group^{1,2,3}



¹Prevalences were not calculated for samples with a denominator of less than 50 individuals. This was the case for statin use for both primary and secondary prevention of CVD in low-income countries (except for the total population for secondary prevention), statin use for primary prevention of CVD among those living on <\$1.90/day in lower middle-income countries, statin use for primary prevention of CVD among those living on <\$1.90/day and <\$3.20/day in upper middle-income countries, and statin use for secondary prevention of CVD among those living on <\$1.90/day in upper middle-income countries.

²All prevalence estimates are age-standardized.

³“Statin primary” and “statin secondary” refer to statin use for primary and secondary prevention of CVD, respectively.

Abbreviations: inc=income; dia=diabetes; hypt=hypertension.

Figure 4 depicts hypertension diagnosis and treatment, diabetes treatment, and statin use by poverty level and World Bank country income group.

Table 1. Survey characteristics by region and county¹

Country	Survey	Year ²	Response rate (%) ³	CVD risk factors	Sample size	Median age (y)	Age Range (y)	Female (%)	In extreme poverty (at <\$1.90/day) ⁴ (n, %)	In poverty at <\$3.20/day ⁴ (n, %)	In poverty at <\$5.50/day ⁴ (n, %)	Population in 2015 (thousands) ⁵	GDP per capita ⁶
East Asia and Pacific													
China	GATS	2010	96.0%	smoking	13354	47	15-102	50.6	1495 (11.2)	3819 (28.6)	7144 (53.5)	1371220	9498.08
	CHNS	2009	88.0%	diabetes, hypertension, obesity, overweight	16758	41	15-105	52.8	2178 (13)	5295 (31.6)	9585 (57.2)		8626.53
Indonesia	IFLS	2014	83.0%	diabetes, hypertension, obesity, overweight, smoking	32059	36	15-110	52.3	1987 (6.2)	11156 (34.8)	21351 (66.6)	258383	10003.17
Kiribati	STEPS	2015	55.0%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking, statin use	2138	37	18-69	53.9	275 (12.9)	739 (34.6)	1483 (69.4)	110	1975.8
Lao People's Democratic Republic	STEPS	2013	99.2%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking	2484	39	16-65	59.7	342 (13.8)	1120 (45.1)	1920 (77.3)	6741	5115.6
Mongolia	STEPS	2019	98.1%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking, statin use	6368	41	18-69	54.7	31 (0.5)	254 (4)	1668 (26.2)	2998	12209.25
Myanmar	DHS	2015-2016	97.8%	obesity, overweight, smoking	36691	39	15-98	53.9	1137 (3.1)	7264 (19.8)	21354 (58.2)	52680	5030.26
	STEPS	2014	94.0%	diabetes, dyslipidemia, hypertension, statin use	8191	45	25-64	64.7	335 (4.1)	1859 (22.7)	4955 (60.5)		4737.46

Philippines	GATS	2015	92.1%	smoking	11644	38	15-98	50.4	710 (6.1)	2992 (25.7)	6357 (54.6)	102113	6847.87
Samoa	STEPS	2013	64.0%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking	1720	39	18-64	59.6	18 (1.1)	165 (9.6)	583 (33.9)	193	5490.94
Solomon Islands	STEPS	2015	58.4%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking, statin use	2501	38	17-71	54.8	622 (24.9)	1455 (58.2)	2113 (84.5)	603	2093.50
Timor-Leste	DHS	2016	98.6%	obesity, overweight, smoking	35776	34	15-98	50.1	6868 (19.2)	23504 (65.7)	32842 (91.8)	1196	7566.02
	STEPS	2014	96.3%	diabetes, dyslipidemia, hypertension, statin use	2555	40	18-69	57.6	562 (22)	1683 (65.9)	2345 (91.8)		6466.74
Tonga	STEPS	2017	85.7%	dyslipidemia, hypertension, obesity, overweight, smoking	3782	41	18-69	63.8	34 (0.9)	283 (7.5)	1040 (27.5)	101	5745.95
Tuvalu	STEPS	2015	76.0%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking, statin use	1144	41	18-69	53.9	37 (3.3)	201 (17.6)	534 (46.7)	11	3389.01
Vanuatu	STEPS	2011	94.0%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking	4582	40	25-64	49.1	604 (13.2)	1805 (39.4)	3317 (72.4)	271	2905.90
Vietnam	GATS	2015	95.8%	smoking	8996	44	15-99	55.7	197 (2.2)	845 (9.4)	2806 (31.2)	92677	5608.47

Europe and Central Asia													
Albania	DHS	2017-2018	95.1%	obesity, overweight, smoking	43423	48	15-98	50.4	477 (1.1)	3734 (8.6)	14590 (33.6)	2880	11803.28
	DHS	2008	95.4%	hypertension	6664	33	15-49	55.0	19 (0.3)	353 (5.3)	2072 (31.1)		9154.71
Armenia	DHS	2015-2016	96.2%	obesity, overweight, smoking	22209	46	15-95	53.5	266 (1.2)	2132 (9.6)	8328 (37.5)	2925	8158.63
Georgia	STEPS	2016	75.7%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking	4165	50	17-70	69.5	158 (3.8)	670 (16.1)	1803 (43.3)	3725	9256.15
Kyrgyz Republic	STEPS	2013	100%	diabetes, dyslipidemia, statin use	2550	44	25-64	62.9	56 (2.2)	543 (21.3)	1639 (64.3)	5956	3116.61
	DHS	2012	96.5%	hypertension, obesity, overweight, smoking	22469	38	15-99	51.1	561 (2.5)	3842 (17.1)	14267 (63.5)		2866.63
Romania	SEPHAR	2016	69.1%	diabetes, hypertension, obesity, overweight, smoking	1970	47	18-80	52.5	55 (2.8)	163 (8.3)	342 (17.4)	19815	21782.13
Tajikistan	DHS	2017	99.1%	obesity, overweight, smoking	28094	35	15-98	49.7	561 (2)	4466 (15.9)	12754 (45.4)	8454	2923.67
	STEPS	2016	94.0%	diabetes, dyslipidemia, hypertension, statin use	2668	39	18-70	58.8	82 (3.1)	432 (16.2)	1267 (47.5)		2784.68
Turkey	DHS	2013	89.9%	obesity, overweight	9029	32	15-49	100.0	27 (0.3)	243 (2.7)	966 (10.7)	78529	21610.49
Latin America and the Caribbean													
Bolivia	DHS	2008	98.8%	obesity, overweight, smoking	47306	35	15-99	51.2	5203 (11)	9461 (20)	18449 (39)	10869	5126.20
Brazil	PNC	2013	86.0%	hypertension, obesity, overweight, smoking	156346	38	15-109	52.2	4846 (3.1)	12351 (7.9)	30174 (19.3)	204471	15535.63

Costa Rica	GATS	2015	94.1%	smoking	8607	43	15-99	58.8	129 (1.5)	352 (4.1)	1032 (12)	4847	14617.15
Dominican Republic	DHS	2013	95.5%	obesity, overweight, smoking	27422	36	15-98	48.3	603 (2.2)	2769 (10.1)	8199 (29.9)	10281	12183.40
Ecuador	STEPS	2017-2018	69.4%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking, statin use	4576	40	18-69	57.5	151 (3.3)	443 (9.7)	1107 (24.2)	16212	10412.20
Guatemala	DHS	2014-2015	98.7%	obesity, overweight, smoking	62325	33	15-95	53.4	5297 (8.5)	15144 (24.3)	31037 (49.8)	16252	7292.71
Haiti	DHS	2016-2017	99.7%	obesity, overweight, smoking	36895	34	15-98	52.8	9039 (24.5)	18558 (50.3)	28999 (78.6)	10695	1653.00
Honduras	DHS	2011-2012	99.8%	obesity, overweight, smoking	60494	32	15-99	50.7	11493 (19)	21596 (35.7)	33997 (56.2)	9112	3984.50
Mexico	GATS	2015	82.7%	smoking	14664	40	15-104	59.7	425 (2.9)	1422 (9.7)	4237 (28.9)	121858	17495.16
	MXFLS	2009-2012	90.0%	diabetes, dyslipidemia, hypertension, obesity, overweight	29563	33	15-99	51.4	1241 (4.2)	3665 (12.4)	9607 (32.5)		16520.26
Panama	GATS	2013	88.4%	smoking	16962	40	15-100	54.7	474 (2.8)	1373 (8.1)	3087 (18.2)	3968	19393.16
Peru	DHS	2012	94.3%	hypertension, obesity, overweight	68566	37	15-98	49.9	3291 (4.8)	8433 (12.3)	18444 (26.9)	30470	11185.81
Uruguay	GATS	2009	95.2%	smoking	5581	46	15-101	52.8	11 (0.2)	100 (1.8)	546 (9.8)	3412	15962.91
Middle East and North Africa													
Egypt	DHS	2015	95.0%	hypertension, smoking	14862	32	15-59	53.1	237 (1.6)	2704 (18.2)	9571 (64.4)	92442	10242.53
	DHS	2014	98.4%	obesity, overweight	75510	34	15-98	48.0	1208 (1.6)	18197 (24.1)	53159 (70.4)		10032.48
Iran	STEPS	2016	98.4%	diabetes, hypertension, obesity, overweight, smoking, statin use	30109	43	18-100	51.6	120 (0.4)	933 (3.1)	4124 (13.7)	78492	18663.54
Jordan	STEPS	2019	84.0%	diabetes,	5527	38	18-69	60.1	5 (0.1)	102 (2.0)	888 (17.5)	9266	8309.30

				dyslipidemia, hypertension, statin use									
	DHS	2017-2018	98.3%	obesity, overweight, smoking	58965	32	15-95	49.0	58 (0.1)	1179 (2.0)	10318 (17.5)		8309.30
Yemen	DHS	2013	96.3%	obesity, overweight, smoking	66809	30	15-98	48.7	11424 (17.1)	33204 (49.7)	53714 (80.4)	26497	3938.89
South Asia													
Bangladesh	DHS	2017-2018	99.4%	diabetes, hypertension, obesity, overweight	57279	35	15-95	52.7	6873 (12)	28639 (50)	47770 (83.4)	156256	3879.16
	GATS	2017	90.8%	smoking	12783	36	15-100	52.4	1661 (13)	6544 (51.2)	10724 (83.9)		3634.32
Bhutan	STEPS	2014	96.9%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking, statin use	2753	39	17-69	61.0	52 (1.9)	374 (13.6)	1153 (41.9)	727	7954.38
India	GATS	2017	92.9%	smoking	74037	37	15-110	54.4	14733 (19.9)	42053 (56.8)	63153 (85.3)	1310	6516.17
	DHS	2015-2016	96.0%	diabetes, hypertension, obesity, overweight	757655	30	15-54	85.5	160622 (21.2)	440955 (58.2)	650067 (85.8)		6145.29
Pakistan	DHS	2017-2018	98.9%	obesity, overweight, smoking	60051	31	15-98	50.8	2642 (4.4)	21438 (35.7)	45758 (76.2)	199426	4927.92
Sub-Saharan Africa													
Angola	DHS	2015-2016	99.4%	smoking	35624	31	15-98	53.3	16636 (46.7)	24580 (69)	31099 (87.3)	27884	6644.86
Benin	STEPS	2015	98.6%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking, statin use	4887	36	18-69	52.4	2423 (49.6)	3723 (76.2)	4427 (90.6)	10575	1987.14
Botswana	GATS	2017	80.0%	smoking	4643	37	15-108	58.8	598 (12.9)	1643 (35.4)	2697 (58.1)	2120	16165.34
	STEPS	2014	63.0%	diabetes, dyslipidemia,	3972	34	15-69	66.8	591 (14.9)	1441 (36.3)	2323 (58.5)		16175.24

				hypertension, obesity, overweight, statin use									
Burkina Faso	DHS	2010	99.2%	obesity, overweight, smoking	40887	33	15-99	52.6	21710 (53.1)	33036 (80.8)	38352 (93.8)	18110	1423.38
Burundi	DHS	2016-2017	99.7%	obesity, overweight, smoking	40137	30	15-98	52.9	28176 (70.2)	35119 (87.5)	38812 (96.7)	10160	689.01
Cabo Verde	STEPS	2007	99.8%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking	1742	41	25-64	61.9	146 (8.4)	468 (26.9)	935 (53.7)	524	5768.87
Cameroon	DHS	2011	99.4%	obesity, overweight, smoking	31142	32	15-98	50.8	9155 (29.4)	16256 (52.2)	23449 (75.3)	23298	3352.06
Chad	DHS	2014-2015	98.9%	obesity, overweight, smoking	44853	30	15-98	51.6	17133 (38.2)	29782 (66.4)	38663 (86.2)	14111	2052.22
Comoros	DHS	2012	96.3%	obesity, overweight, smoking	14087	32	15-99	51.4	2676 (19)	5592 (39.7)	9100 (64.6)	777	2483.41
	STEPS	2011	96.5%	diabetes, hypertension	5172	40	25-64	69.6	977 (18.9)	2048 (39.6)	3341 (64.6)		2465.32
Congo	DHS	2011-2012	99.8%	obesity, overweight	26370	34	15-99	51.8	10495 (39.8)	16955 (64.3)	22150 (84)	4856	5415.11
Congo Democratic Republic	DHS	2013-2014	99.9%	obesity, overweight, smoking	45319	31	15-96	51.0	35031 (77.3)	41421 (91.4)	44367 (97.9)	76244	741.17
Cote d'Ivoire	DHS	2011-2012	98.1%	obesity, overweight	27616	32	15-99	49.6	8284 (30)	16321 (59.1)	22838 (82.7)	23226	2696.19
Ethiopia	GATS	2016	93.4%	smoking	10150	30	15-101	54.4	3004 (29.6)	6891 (67.9)	9104 (89.7)	100835	1617.32
	STEPS	2015	95.5%	diabetes, dyslipidemia, hypertension, statin use	8888	34	18-69	57.7	2737 (30.8)	6123 (68.9)	8016 (90.2)		1518.47
	DHS	2008	97.6%	obesity, overweight	38939	32	15-98	52.7	14212 (36.5)	29749 (76.4)	36758 (94.4)		927.51
Eswatini	STEPS	2014	81.8%	diabetes, dyslipidemia,	3444	34	15-71	64.3	1139 (33.1)	1921 (55.8)	2583 (75)	1104	9309.1

				hypertension, obesity, overweight, smoking, statin use									
Gabon	DHS	2012	99.3%	obesity, overweight	23271	37	15-99	51.6	1000 (4.3)	3281 (14.1)	8610 (37)	1948	16225.39
Gambia	DHS	2013	95.0%	obesity, overweight, smoking	27865	30	15-99	53.2	4541 (16.3)	12399 (44.5)	21177 (76)	2086	1500.51
	STEPS	2010	77.9%	hypertension	3871	36	25-64	54.3	983 (25.4)	2070 (53.5)	3123 (80.7)		1551.59
Ghana	DHS	2014	98.5%	obesity, overweight, smoking	24893	35	15-98	53.0	2962 (11.9)	7467 (30)	14164 (56.9)	27849	3791.28
	SAGE	2008	79.4%	hypertension	5565	60	18-114	48.8	1012 (18.2)	2253 (40.5)	3817 (68.6)		2813.21
Guinea	DHS	2012	99.2%	obesity, overweight, smoking	25184	34	15-98	55.0	9091 (36.1)	17855 (70.9)	23295 (92.5)	11432	2337.95
Kenya	STEPS	2015	95.0%	diabetes, dyslipidemia, hypertension, statin use	4337	36	18-69	58.9	1609 (37.1)	2884 (66.5)	3755 (86.6)	47878	2797.86
	DHS	2014	99.0%	obesity, overweight, smoking	81959	31	15-95	51.3	31554 (38.5)	55240 (67.4)	71796 (87.6)		2713.30
Lesotho	DHS	2014	90.8%	hypertension, obesity, overweight, smoking	18726	34	15-95	53.9	6797 (36.3)	10486 (56)	14419 (77)	2059	2811.24
Liberia	STEPS	2011	87.1%	diabetes, hypertension, obesity, overweight, smoking	1788	35	24-64	53.2	974 (54.5)	1482 (82.9)	1711 (95.7)	4472	1154.41
Madagascar	DHS	2009	98.8%	obesity, overweight, smoking	44648	31	15-99	50.2	34334 (76.9)	40540 (90.8)	43487 (97.4)	24234	1523.02
Malawi	DHS	2015-2016	99.2%	obesity, overweight, smoking	61989	30	15-98	51.5	42896 (69.2)	55170 (89)	59881 (96.6)	16745	1142.55
	STEPS	2009	95.5%	diabetes, dyslipidemia, hypertension	4940	36	25-64	65.8	3522 (71.3)	4391 (88.9)	4752 (96.2)		1037.60

Mozambique	DHS	2011	99.8%	obesity, overweight, smoking	30998	32	15-98	52.7	20675 (66.7)	26627 (85.9)	29262 (94.4)	27042	984.47
	STEPS	2005	98.3%	diabetes, dyslipidemia, hypertension	3191	38	25-64	56.7	2390 (74.9)	2907 (91.1)	3085 (96.7)		757.97
Namibia	DHS	2013	96.9%	diabetes, hypertension, obesity, overweight, smoking	24760	33	15-99	52.0	4209 (17)	9111 (36.8)	14137 (57.1)	2315	9599.65
Niger	DHS	2012	98.0%	obesity, overweight, smoking	27968	33	15-99	52.0	13648 (48.8)	22849 (81.7)	26597 (95.1)	20002	859.79
	STEPS	2007	91.3%	diabetes, hypertension	2670	37	15-64	45.8	1933 (72.4)	2419 (90.6)	2584 (96.8)		772.37
Nigeria	DHS	2015	99.4%	obesity, overweight, smoking	99588	33	15-98	50.8	45013 (45.2)	73993 (74.3)	91919 (92.3)	181137	5315.82
Rwanda	DHS	2014-2015	99.9%	obesity, overweight, smoking	30409	31	15-98	54.0	17302 (56.9)	24570 (80.8)	28006 (92.1)	11369	1671.91
	STEPS	2012	99.8%	diabetes, dyslipidemia, hypertension	7002	33	15-64	61.6	4208 (60.1)	5783 (82.6)	6497 (92.8)		1558.62
Sao Tome and Principe	STEPS	2009	95.0%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking	2376	38	25-64	55.8	814 (34.3)	1696 (71.4)	2200 (92.6)	199	2460.81
Senegal	GATS	2015	97.0%	smoking	4347	33	15-100	54.8	1547 (35.6)	2890 (66.5)	3812 (87.7)	14578	3001.82
	DHS	2010-2011	98.4%	obesity, overweight	40097	31	15-98	54.8	15437 (38.5)	27426 (68.4)	35445 (88.4)		2775.70
South Africa	DHS	2016	83.4%	diabetes, hypertension, obesity, overweight, smoking	25757	36	15-98	53.6	4662 (18.1)	9452 (36.7)	14526 (56.4)	55386	12214.95
Tanzania	DHS	2015-2016	98.4%	obesity, overweight, smoking	32731	33	15-95	50.0	16169 (49.4)	25268 (77.2)	30112 (92)	51482	2613.36
	STEPS	2012	94.7%	diabetes,	5537	40	23-65	52.3	2746 (49.6)	4374 (79)	5149 (93)		2362.93

				dyslipidemia, hypertension									
Togo	DHS	2013-2014	99.1%	obesity, overweight, smoking diabetes, dyslipidemia, hypertension	24106	33	15-98	52.4	12559 (52.1)	17983 (74.6)	21888 (90.8)	7323	1379.40
	STEPS	2010	91.0%	obesity, overweight, smoking diabetes, dyslipidemia, hypertension	4204	32	15-64	50.5	2329 (55.4)	3211 (76.4)	3817 (90.8)		1241.92
Uganda	DHS	2016	98.2%	obesity, overweight, smoking	44343	30	15-98	51.8	17692 (39.9)	30596 (69)	38755 (87.4)	38225	1767.50
	STEPS	2014	99.0%	diabetes, dyslipidemia, hypertension, statin use	3782	33	18-69	57.6	1456 (38.5)	2586 (68.4)	3301 (87.3)		1722.49
Zambia	DHS	2018	99.1%	smoking diabetes, dyslipidemia, hypertension, obesity, overweight, statin use	32301	31	15-98	51.6	19025 (58.9)	24871 (77.0)	29232 (90.5)	15879	3747.97
	STEPS	2017	65.0%	smoking diabetes, dyslipidemia, hypertension, obesity, overweight, statin use	4126	35	18-69	60.9	2430 (58.9)	3168 (76.8)	3729 (90.4)		3717.67
Zanzibar	STEPS	2011	91.0%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking	2391	40	24-64	60.3	1185 (49.6)	1900 (79.5)	2228 (93.2)	404	2329.33
Zimbabwe	DHS	2015	98.8%	obesity, overweight, smoking	23688	32	15-95	53.4	6869 (29.0)	13336 (56.3)	18666 (78.8)	13814	2509.01
Total			96.3⁷ (91.0-98.8)⁸		3,269,557⁹	35.0⁷ (32.0-39.0)⁸		53.1⁷ (51.4-57.5)⁸	792,228⁹	1,598,609⁹	2,346,687⁹	3,910,153⁹	2696.19⁷ (2093.50-8626.53)⁸

¹Values are unweighted (i.e., do not account for the complex survey design).
²Year(s) in which the data collection for the survey was carried out.
³This includes both the household and the individual response rate.
⁴Poverty levels are in constant 2011 international dollars as provided by the World Bank ^{27,56,57}.
⁵Population in 2015 as estimated by the United Nations, Population Division, Department of Economic and Social Affairs ³⁷.
⁶This is the GDP per capita in constant 2011 international dollars (as estimated by the World Bank ³⁸) for the year in which data were collected for the survey.
⁷This is the median value with each survey having the same weight.
⁸These are interquartile ranges.
⁹This is the sum across all countries.

Abbreviations: CHNS=China Health and Nutrition Survey, DHS=Demographic and Health Surveys, GATS=Global Adult Tobacco Survey, GDP=Gross domestic product, IFLS=Indonesian Family Life Survey, MXFLS=Mexican Family Life Survey, PNC=Pesquisa Nacional de Saude, PPP=purchasing-power-parity-adjusted dollars, SAGE=Study on global AGEing and adult health, SEPHAR=Study for the Evaluation of Prevalence of Hypertension and cardiovascular risk in Romania; STEPS= WHO STEPwise approach to NCD risk factor surveillance; y=years.